Drug
Gtx 102
Gtx 102: highest development phase Phase 3, developed by Ultragenyx Pharmaceutical. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Ultragenyx Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| GTX-102 NCT06617429 | Phase 3 | Angelman Syndrome |
| GTX-102 NCT06415344 | Phase 3 | Angelman Syndrome |
| GTX-102 NCT07157254 | Phase 2 | Angelman Syndrome |
| GTX-102 NCT04259281 | Phase 1/2 | Angelman Syndrome |
Latest
No recent events.
Follow Gtx 102 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.